Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects

References

• Aoyama T, Yamano S, Waxman DJ, et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. Journal of Biological Chemistry 1989; 264: 10388–10395
   PubMed Web of Science ®Google Scholar
• Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Research 1976; 3: 2303–2308
   PubMed Web of Science ®Google Scholar
• Brunet M, Millán O, Jiménez O, et al. New concepts in cyclosporine pharmacokinetics and dynamic monitoring: The impact of concomitant immunosuppression on target C2 concentrations. Transplantation Proceedings 2004; 36(Suppl 2S)437S–41S
   PubMed Web of Science ®Google Scholar
• Clase CM, Mahalati K, Kiberd BA, et al. Adequate early cyclosporine exposure is critical to prevent renal allograft rejection: Patients monitored by absorption profiling. American Journal of Transplantation 2002; 2: 789–795
   PubMed Web of Science ®Google Scholar
• Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. Journal of Pharmacology and Experimental Therapeutics 2001; 299: 825–831
   PubMed Web of Science ®Google Scholar
• Evans WE, McLeod HL. Pharmacogenomics—drug disposition, drug targets and side effects. New England Journal of Medicine 2003; 348: 538–549
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV. Pharmacogenetics: Translating functional genomics into rational therapeutics. Science 1999; 286: 487–491
   PubMed Web of Science ®Google Scholar
• Feng HJ, Huang SL, Wang W, Zhou HH. The induction effect of refampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene dose. British Journal of Clinical Pharmacology 1998; 45: 27–29
   PubMed Web of Science ®Google Scholar
• Fukushima-Uesaka H, Saito Y, Watanabe H, et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Human Mutation 2004; 26: 100–108
   Google Scholar
• Guengerich FP. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annual Review of Pharmacology and Toxicology 1999; 38: 389–430
   Google Scholar
• Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineur ininhibitors cyclosporine and tacrolimus. Clinical Pharmacology and Therapeutics 2003; 74: 245–254
   PubMed Web of Science ®Google Scholar
• Hsieh KP, Lin YY, Cheng CL, et al. Novel mutations of CYP3A4 in Chinese. Drug Metabolism and Disposition 2001; 29: 268
   PubMed Web of Science ®Google Scholar
• Hu YF, He J, Chen GL, et al. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chem Acta 2005; 353: 187–192
   PubMed Web of Science ®Google Scholar
• Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity o human hepatic CYP3A. Biochemical Pharmacology 1992; 44: 275–283
   PubMed Web of Science ®Google Scholar
• Kelly P, Kahan BD. Review: Metabolism of immunosuppressant drugs. Current Drug Metabolism 2002; 3: 275–287
   PubMed Web of Science ®Google Scholar
• Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine metabolizing enzyme explains interactions of cyclosporine with other drugs. Clinical Pharmacology and Therapeutics 1988; 43: 630–635
   PubMed Web of Science ®Google Scholar
• Lown KS, Kolars JC, Thummel KE, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metabolism and Disposition 1994; 22: 947–955
   PubMed Web of Science ®Google Scholar
• Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Transplantation 1999; 68: 55–62
   PubMed Web of Science ®Google Scholar
• Min DI, Ellingrod VL. Association of the CYP3A4*1B 5′-flanking region polymorphism with cyclosporine pharmacokinetics in the healthy subjects. Therapeutic Drug Monitoring 2003; 25: 305–309
   PubMed Web of Science ®Google Scholar
• Ozdemir V, Kalowa W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method. Pharmacogenetics 2000; 10: 373–388
   Google Scholar
• Pichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interaction. Screening for inducers and inhibitors of cytochrome P450 (cyclsoporin oxidase) in primary culture of human hepatocytes and in liver microsomes. Drug Metabolism and Disposition 1990; 18: 595–606
   PubMed Web of Science ®Google Scholar
• Taylor PJ, Jones CE, Martin PT, et al. Microscale high-performance liquid chromatography-electrospray tandem mass spectrometry assay for cyclosporin A in blood. Journal of Chromatology B. Biomedical Sciences and Applications 1998; 705: 289–294
   PubMed Web of Science ®Google Scholar
• Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annual Review of Pharmacology and Toxicology 1998; 39: 1–17
   Google Scholar
• von Ahsen N, Richter M, Group C, et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporine A trough concentration or rejection incidence in stable renal transplant recipients. Clinical Chemistry 2001; 47: 1048–1052
   PubMed Web of Science ®Google Scholar
• Wang JH, Liu ZQ, Wang W, Cheng XP, Shu Y, He N, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clinical Pharmacology and Therapeutics 2001; 70: 42–47
   PubMed Web of Science ®Google Scholar
• Watkins PB, Wrighton SA, Maurel P, et al. Identification of an inducible from cytochrome P-450 in human liver. Proceedings of the National Academy of Sciences. USA 1985; 82: 6310–6314
   Google Scholar
• Wójcikowski J, Pichard-Garcia L, Maurel P, Daniel WA. Perazine as a potent inhibitor of human CYP1A2 but not CYP3A4. Polish Journal of Pharmacology 2002; 54: 407–410
   PubMedGoogle Scholar
• Wrighton SA, Ring BJ, Watkins PB, Vandenbranden M. Identification of a polymorphically expressed member of the human cytochrome P-450 family. Molecular Pharmacology 1989; 36: 97–105
   PubMed Web of Science ®Google Scholar
• Xiao ZS, Goldstein JA, Xie HG, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. Journal of Pharmacology and Experimental Therapeutics 1997; 281: 604–609
   PubMed Web of Science ®Google Scholar
• Zhu B, Liu ZQ, Chen GL, et al. The distribution and gender difference of CYP3A activity in Chinese subjects. British Journal of Clinical Pharmacology 2003; 55: 264–269
   PubMed Web of Science ®Google Scholar